Etanercept Leads to Smooth Suppression of Inflammation in SpA (the ELSSI study)
Phase of Trial: Phase III
Latest Information Update: 19 Jul 2016
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms ELSSI
- 11 Jul 2016 Status changed from recruiting to completed.
- 28 Jan 2016 Planned End Date changed from 31 Dec 2015 to 30 Jun 2016 Accrual to Date is 73% according to the United Kingdom Clinical Research Network record.
- 28 Jan 2016 Accrual to Date is 77% according to the United Kingdom Clinical Research Network record.